Roche Holding AG (RHHBY) said on Tuesday that the European Commission has approved Gazyva/Gazyvaro, in combination with mycophenolate mofetil (MMF), for the treatment of adult patients with active lupus nephritis.
The approval is based on positive results from the phase II NOBILITY and phase III REGENCY studies.
Gazyva/Gazyvaro is already approved for adults with lupus nephritis in the United States and is used in more than 100 countries to treat different types of blood cancers.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.